- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- Bydureon pen gets FDA approval
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
- Diplomat becomes distributor of recently approved cancer drug
WILMINGTON, Del. The Food and Drug Administration has approved a new dosage of an AstraZeneca drug for treating breast cancer, AstraZeneca said Friday.
The Anglo-Swedish drug maker announced the approval of the 500-mg dose of the injected drug Faslodex (fulvestrant) for treating breast cancer that has spread to other parts of the body –– also known as metastasis –– in postmenopausal women after they have received anti-estrogen therapy. The new dosage replaces the previous 250-mg dose of the drug.
“This approval is an important advancement for women with metastatic breast cancer, where the treatment approach is centered on delaying disease progression,” AstraZeneca medical director Gershon Locker said. “Faslodex at 250 mg has been an important treatment option for many women, and we now have data to show that the new 500-mg dosing regimen can improve progression-free survival compared with the 250-mg dose.”